Bausch Health Companies Inc. (BHC) SEC Filings & Earnings Calls

Failed Phase 3 trial leads to goodwill impairment

“both clinical trials failed to achieve their primary endpoints” · word for word

Volume decline in Salix and Diversified due to channel exits

“a decrease in volumes of $57 million” · word for word

High debt load with $20.2B total debt

“Total debt obligations │ $ │ 20,239”

Tariff exposure on pharmaceutical imports

“We are evaluating the impact of such tariffs and do not expect a material impact on our business and consolidated results of operations.” · word for word

Tariff uncertainty: The company notes evolving tariff landscape and potential adverse impacts, though current guidance includes estimated tariff effects.

“The rapid recent developments in the evolving landscape of tariffs and responses have resulted in uncertainty regarding these measures and the effects they may have. We continue to assess the direct and indirect impacts on our businesses of such tariffs, including retaliatory tariffs and other trade protectionist measures as the situation develops, and there” · word for word

High debt levels: Despite debt reduction, the company carries significant net debt and relies on non-GAAP metrics for guidance.

“Reduced Net Debt by one of our largest amounts since our 2022 debt refinancing. The company only provides guidance on a non-GAAP basis and does not reconcile forward-looking Adjusted EBITDA to GAAP net income.”

Loss of board member with pharmaceutical expertise

“Michael Goettler resigned from the Board; no replacement announced.”

Clinical trial failure

“both clinical trials failed to achieve their primary endpoint” · word for word

High leverage and debt maturity wall

“Total debt obligations ... $20,212 ... $3,765 million due in 2028, $4,123 million due in 2030”

Tariff exposure

“the President imposed a one hundred percent (100%) tariff on patented pharmaceutical products and ingredients imported after September 29, 2026” · word for word

Interest rate risk

“The weighted average stated rate of interest as of March 31, 2026 and 2025 was 8.47% and 7.71%, respectively.” · word for word

Goodwill impairment of $1,426M related to Salix RED-C program signals potential overpayment or underperformance in that asset.

“goodwill impairment charge related to Salix's RED-C program of $1,426 million.” · word for word

Diversified segment revenue declined 10% YoY, indicating ongoing loss of exclusivity and competitive pressure.

“Diversified segment reported revenues were $185 million... decrease of $20 million, or 10%.” · word for word

Tariff uncertainty could impact supply chain and costs; company notes evolving situation.

“The rapid recent developments in the evolving landscape of tariffs and responses have resulted in uncertainty regarding these measures and the effects they may have.” · word for word

High debt levels and refinancing risk

“Refinanced $9,600M of debt maturities through a series of transactions, providing flexibility for the potential monetization of our Bausch + Lomb equity stake.” · word for word

Dependence on Bausch + Lomb separation

“Given that it had been 5 years since the Separation Bonuses were awarded and the full separation of B+L had not yet occurred” · word for word

Xifaxan patent litigation risk

“The Company has filed lawsuits against third-party generic manufacturers that have sent the Company Notices of Paragraph IV Certification for Trulance® and Xifaxan®.” · word for word

Drug pricing regulation risk (IRA)

“the selection by the Centers for Medicare & Medicaid Services (CMS) of Xifaxan® for the second round of negotiation under the drug price negotiation program for initial price applicability in 2027” · word for word

Tariff uncertainty could impact supply chain and costs, but not quantified.

“The rapid recent developments in the evolving landscape of tariffs and responses have resulted in uncertainty regarding these measures and the effects they may have.”

Diversified Products segment declining (-1% FY), may indicate portfolio pressure.

“Diversified Products segment...$937 million...compared with $950 million...a decrease of 1%.”

High Debt and Refinancing Risk

“Total debt obligations $20,529 million as of September 30, 2025, with significant maturities in 2028 and beyond.”

Product Recall Impact

“Voluntary recall of certain enVista IOL products impacting Bausch + Lomb segment profit.” · word for word

Interest Rate Exposure

“Weighted average stated rate of interest increased to 8.57% from 7.88%, and interest expense rose 15%.”

Xifaxan Revenue Concentration

“Xifaxan product line accounted for approximately 85% of Salix segment revenues.” · word for word

International and Diversified segments declining; tariff uncertainty may pressure future results.

“International -2%, Diversified -4% YoY; tariff impacts mentioned but not quantified.”

High debt load and interest expense remain a concern; net income impacted by financing costs.

“GAAP net income $179M vs operating income $619M; significant interest expense implied.”